Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Candin Articles

Japan stock market week to April 24, 2006

1 May 2006

Japan stock market week to April 17, 2006

24 April 2006

Tokyo pharma stocks - week to September 6

13 September 2004

Fujisawa net income leaps 44.8%, despite only 3.5% sales growth

10 May 2004

Fujisawa updates status of pipeline

8 March 2004

Fujisawa's Funguard sales up on forecast

5 January 2004

Tokyo pharma stocks - week to Sept 29

6 October 2003

Tokyo pharma stocks - week to July 28

4 August 2003

Kaken, Elitra to ally on antifungal R&D

3 March 2003

Fujisawa files for new antifungal in Europe

3 March 2003

Fujisawa says US entry of micafungin delayed

10 February 2003

Fujisawa says US entry of micafungin delayed

10 February 2003

KV Pharma to sell thrush product in Brazil

15 July 2002

Elitra Pharmaceuticals to acquire Mycota Biosciences

19 October 2000

New Antifungals Highlighted At ICAAC

13 November 1997

Roche Purchases KV Stock

7 April 1997

Cortecs' Oral Calcitonin Nears First Filing

24 March 1997

Cortecs Furthers Clinical Trials

25 November 1996

Xoma Selects Lead Antifungal

22 January 1996

Cortecs Reduces Interim Loss

20 March 1995

SEA SQUIRT ANTIFUNGAL

6 September 1993

FERRER LICENSES ANTIFUNGAL TO SB

22 March 1993

DERMATOLOGISTS HIGHLIGHT SPORANOX

29 June 1992

Showing 1-23 of 23 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS